Abstract
This paper provides an update on orphan product development since the passage of the Orphan Drug Act in 1983. The number of drugs approved and marketed to treat rare diseases and disorders has increased substantially since passage of the act, despite their limited commercial value. Implementation of this legislation continues to evolve to fit changing trends, but by all measures the Orphan Drug Act has been an immense success.
Get full access to this article
View all access options for this article.